213 research outputs found
Assessing composition gradients in multifilamentary superconductors by means of magnetometry methods
We present two magnetometry-based methods suitable for assessing gradients in
the critical temperature and hence the composition of multifilamentary
superconductors: AC magnetometry and Scanning Hall Probe Microscopy. The
novelty of the former technique lies in the iterative evaluation procedure we
developed, whereas the strength of the latter is the direct visualization of
the temperature dependent penetration of a magnetic field into the
superconductor. Using the example of a PIT Nb3Sn wire, we demonstrate the
application of these techniques, and compare the respective results to each
other and to EDX measurements of the Sn distribution within the sub-elements of
the wire.Comment: 7 pages, 8 figures; broken hyperlinks are due to a problem with arXi
Rotating sample magnetometer for cryogenic temperatures and high magnetic fields
We report on the design and implementation of a rotating sample magnetometer
(RSM) operating in the variable temperature insert of a cryostat equipped with
a high-field magnet. The limited space and the cryogenic temperatures impose
the most critical design parameters: the small bore size of the magnet requires
a very compact pick-up coil system and the low temperatures demand a very
careful design of the bearings. Despite these difficulties the RSM achieves
excellent resolution at high magnetic field sweep rates, exceeding that of a
typical vibrating sample magnetometer by about a factor of ten. In addition the
gas-flow cryostat and the high-field superconducting magnet provide a
temperature and magnetic field range unprecedented for this type of
magnetometer.Comment: 10 pages, 5 figure
Recommended from our members
Magnetic granularity in pulsed laser deposited YBCO films on technical templates at 5 K
The manifestation of granularity in the superconducting properties of pulsed laser deposited YBCO films on commercially available metallic templates was investigated by scanning Hall probe microscopy at 5 K and was related to local orientation mapping of the YBCO layer. The YBCO films on stainless steel templates with a textured buffer layer of yttrium stabilized ZrO2 grown by alternating beam assisted deposition have a mean grain size of less than with a sharp texture. This results in a homogeneous trapped field profile and spatial distribution of the current density. On the other hand, YBCO films on biaxially textured NiW substrates show magnetic granularity that persists down to a temperature of 5 K and up to an applied magnetic field of 4 T. The origin of the granular field profile is directly correlated to the microstructural properties of the YBCO layer adopted from the granular NiW substrate which leads to a spatially inhomogeneous current density. Grain-to-grain in-plane tilts lead to grain boundaries that obstruct the current while out-of-plane tilts mainly affect the grain properties, resulting in areas with low . Hence, not all grain boundaries cause detrimental effects on since the orientation of individual NiW grains also contributes to observed inhomogeneity and granularity
Ductus venosus shunting in the fetal venous circulation: regulatory mechanisms, diagnostic methods and medical importance
K E Y W O R D S
ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction
N/
Twin-Twin Transfusion Syndrome: study protocol for developing, disseminating, and implementing a core outcome set.
BACKGROUND: Twin-Twin Transfusion Syndrome (TTTS) is associated with an increased risk of perinatal mortality and morbidity. Several treatment interventions have been described for TTTS, including fetoscopic laser surgery, amnioreduction, septostomy, expectant management, and pregnancy termination. Over the last decade, fetoscopic laser surgery has become the primary treatment. The literature to date reports on many different outcomes, making it difficult to compare results or combine data from individual studies, limiting the value of research to guide clinical practice. With the advent and ongoing development of new therapeutic techniques, this is more important than ever. The development and use of a core outcome set has been proposed to address these issues, prioritising outcomes important to the key stakeholders, including patients. We aim to produce, disseminate, and implement a core outcome set for TTTS. METHODS: An international steering group has been established to oversee the development of this core outcome set. This group includes healthcare professionals, researchers and patients. A systematic review is planned to identify previously reported outcomes following treatment for TTTS. Following completion, the identified outcomes will be evaluated by stakeholders using an international, multi-perspective online modified Delphi method to build consensus on core outcomes. This method encourages the participants towards consensus 'core' outcomes. All key stakeholders will be invited to participate. The steering group will then hold a consensus meeting to discuss results and form a core outcome set to be introduced and measured. Once core outcomes have been agreed, the next step will be to determine how they should be measured, disseminated, and implemented within an international context. DISCUSSION: The development, dissemination, and implementation of a core outcome set in TTTS will enable its use in future clinical trials, systematic reviews and clinical practice guidelines. This is likely to advance the quality of research studies and their effective use in order to guide clinical practice and improve patient care, maternal, short-term perinatal outcomes and long-term neurodevelopmental outcomes. TRIAL REGISTRATION: Core Outcome Measures in Effectiveness Trials (COMET), 921 Registered on July 2016. International Prospective Register of Systematic Reviews (PROSPERO), CRD42016043999 . Registered on 2 August 2016
Achieving orphan designation for placental insufficiency: annual incidence estimations in Europe
Objective
To determine whether a novel therapy for placental insufficiency could achieve orphan drug status by estimating the annual incidence of placental insufficiency, defined as an estimated fetal weight below the 10th centile in the presence of abnormal umbilical artery Doppler velocimetry, per 10 000 European Union (EU ) population as part of an application for European Medicines Agency (EMA ) orphan designation.
Design
Incidence estimation based on literature review and published national and EU statistics.
Setting and population
European Union.
Methods
Data were drawn from published literature, including national and international guidelines, international consensus statements, cohort studies and randomised controlled trials, and published national and EU statistics, including birth rates and stillbirth rates. Rare disease databases were also searched.
Results
The proportion of affected pregnancies was estimated as 3.17% (95% CI 2.93–3.43%), using a weighted average of the results from two cohort studies. Using birth rates from 2012 and adjusting for a pregnancy loss rate of 1/100 gave an estimated annual incidence of 3.33 per 10 000 EU population (95% CI 3.07–3.60 per 10 000 EU population). This fell below the EMA threshold of 5 per 10 000 EU population.
Conclusions
Maternal vascular endothelial growth factor gene therapy for placental insufficiency was granted EMA orphan status in 2015 after we demonstrated that it is a rare, life‐threatening or chronically debilitating and currently untreatable disease. Developers of other potential obstetric therapies should consider applying for orphan designation, which provides financial and regulatory benefits
Maternal PlGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction
BACKGROUNDSevere, early-onset fetal growth restriction (FGR) causes significant fetal and neonatal mortality and morbidity. Predicting the outcome of affected pregnancies at the time of diagnosis is difficult, thus preventing accurate patient counseling. We investigated the use of maternal serum protein and ultrasound measurements at diagnosis to predict fetal or neonatal death and 3 secondary outcomes: fetal death or delivery at or before 28+0 weeks, development of abnormal umbilical artery (UmA) Doppler velocimetry, and slow fetal growth.METHODSWomen with singleton pregnancies (n = 142, estimated fetal weights [EFWs] below the third centile, less than 600 g, 20+0 to 26+6 weeks of gestation, no known chromosomal, genetic, or major structural abnormalities) were recruited from 4 European centers. Maternal serum from the discovery set (n = 63) was analyzed for 7 proteins linked to angiogenesis, 90 additional proteins associated with cardiovascular disease, and 5 proteins identified through pooled liquid chromatography and tandem mass spectrometry. Patient and clinician stakeholder priorities were used to select models tested in the validation set (n = 60), with final models calculated from combined data.RESULTSThe most discriminative model for fetal or neonatal death included the EFW z score (Hadlock 3 formula/Marsal chart), gestational age, and UmA Doppler category (AUC, 0.91; 95% CI, 0.86-0.97) but was less well calibrated than the model containing only the EFW z score (Hadlock 3/Marsal). The most discriminative model for fetal death or delivery at or before 28+0 weeks included maternal serum placental growth factor (PlGF) concentration and UmA Doppler category (AUC, 0.89; 95% CI, 0.83-0.94).CONCLUSIONUltrasound measurements and maternal serum PlGF concentration at diagnosis of severe, early-onset FGR predicted pregnancy outcomes of importance to patients and clinicians.TRIAL REGISTRATIONClinicalTrials.gov NCT02097667.FUNDINGThe European Union, Rosetrees Trust, Mitchell Charitable Trust
EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction
BACKGROUND: Fetal growth restriction (FGR) is a serious obstetric condition for which there is currently no treatment. The EVERREST Prospective Study has been designed to characterise the natural history of pregnancies affected by severe early onset FGR and establish a well phenotyped bio-bank. The findings will provide up-to-date information for clinicians and patients and inform the design and conduct of the EVERREST Clinical Trial: a phase I/IIa trial to assess the safety and efficacy of maternal vascular endothelial growth factor (VEGF) gene therapy in severe early onset FGR. Data and samples from the EVERREST Prospective Study will be used to identify ultrasound and/or biochemical markers of prognosis in pregnancies with an estimated fetal weight (EFW) <3rd centile between 20+0 and 26+6 weeks of gestation. METHODS: This is a 6 year European multicentre prospective cohort study, recruiting women with a singleton pregnancy where the EFW is <3rd centile for gestational age and <600 g at 20+0 to 26+6 weeks of gestation. Detailed data are collected on: maternal history; antenatal, peripartum, and postnatal maternal complications; health economic impact; psychological impact; neonatal condition, progress and complications; and infant growth and neurodevelopment to 2 years of corrected age in surviving infants. Standardised longitudinal ultrasound measurements are performed, including: fetal biometry; uterine artery, umbilical artery, middle cerebral artery, and ductus venosus Doppler velocimetry; and uterine artery and umbilical vein volume blood flow. Samples of maternal blood and urine, amniotic fluid (if amniocentesis performed), placenta, umbilical cord blood, and placental bed (if caesarean delivery performed) are collected for bio-banking. An initial analysis of maternal blood samples at enrolment is planned to identify biochemical markers that are predictors for fetal or neonatal death. DISCUSSION: The findings of the EVERREST Prospective Study will support the development of a novel therapy for severe early onset FGR by describing in detail the natural history of the disease and by identifying women whose pregnancies have the poorest outcomes, in whom a therapy might be most advantageous. The findings will also enable better counselling of couples with affected pregnancies, and provide a valuable resource for future research into the causes of FGR
- …